FDA Determines Regulatory Review Period for INREBIC Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for INREBIC, a human drug product, as required by law after receiving patent extension applications from the US Patent and Trademark Office (USPTO).